No significant expression of Wt1 gene in multiple myeloma patients at diagnosis: Is Wt1 gene expression useful marker for minimal residual disease in multiple myeloma?

被引：0
|
作者：
Ozkul, Yusuf
Caglayan, Ahmet O.
Kocyigit, Ismail
Saatci, Cetin
Akalin, Hilal
Demir, Muzaffer
Altuntas, Fevzi
Cetin, Mustafa
Eser, Bulent
Kaynar, Leylagul
机构：
[1] Erciyes Univ, Kayseri, Turkey
[2] Trakya Univ, Edirne, Turkey
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.4761.4761
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4761
引用
收藏
页码：263B / 263B
页数：1
相关论文
共 50 条
  • [31] LONGITUDINAL FOLLOW UP OF MINIMAL RESIDUAL DISEASE IN AML AFTER SCT WITH QUANTITATIVE EVALUATION OF WT1 GENE EXPRESSION
    Candoni, A.
    Simeone, E.
    Gallina, R.
    Toffoletti, E.
    D'Odorico, C.
    Zanini, F.
    Fanin, R.
    HAEMATOLOGICA, 2012, 97 : 402 - 402
  • [32] PROGNOSTIC IMPACT OF WT1 GENE EXPRESSION QUANTIFICATION DURING MINIMAL RESIDUAL DISEASE MONITORING OF ACUTE PROMYELOCYTIC LEUKEMIA
    Mitrovic, M.
    Tosic, N.
    Suvajdzic, N.
    Djunic, I.
    Vidovic, A.
    Virijevic, M.
    Colovic, N.
    Glumac, I.
    Kostic, T.
    Pavlovic, S.
    Elezovic, I.
    Tomin, D.
    HAEMATOLOGICA, 2015, 100 : 377 - 378
  • [33] Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis
    PritchardJones, K
    Renshaw, J
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (13) : 1311 - 1311
  • [34] Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis
    Baird, PN
    Simmons, PJ
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (04) : 312 - 320
  • [35] WT1 gene expression is significantly inhibited by vorinostat and bortezomib
    Galimberti, S.
    Canestraro, M.
    Khan, R.
    Buda, G.
    Orciuolo, E.
    Guerrini, F.
    Fazzi, R.
    Petrini, M.
    BLOOD REVIEWS, 2007, 21 : S80 - S80
  • [36] In vitro leukemic cell differentiation and WT1 gene expression
    Hernandez-Caballero, E.
    Mayani, H.
    Montesinos, J. J.
    Arenas, D.
    Salamanca, F.
    Penaloza, R.
    LEUKEMIA RESEARCH, 2007, 31 (03) : 395 - 397
  • [37] Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study
    A M Willasch
    B Gruhn
    T Coliva
    M Kalinova
    G Schneider
    H Kreyenberg
    D Steinbach
    G Weber
    I H I M Hollink
    C M Zwaan
    A Biondi
    V H J van der Velden
    D Reinhardt
    G Cazzaniga
    P Bader
    J Trka
    Leukemia, 2009, 23 : 1472 - 1479
  • [38] Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study
    Willasch, A. M.
    Gruhn, B.
    Coliva, T.
    Kalinova, M.
    Schneider, G.
    Kreyenberg, H.
    Steinbach, D.
    Weber, G.
    Hollink, Ihim
    Zwaan, C. M.
    Biondi, A.
    van der Velden, V. H. J.
    Reinhardt, D.
    Cazzaniga, G.
    Bader, P.
    Trka, J.
    LEUKEMIA, 2009, 23 (08) : 1472 - 1479
  • [39] WT1 expression in patients with myelodysplastic syndromes
    Polistina, M. T.
    Tiberio, C.
    Sagristani, M.
    Esposito, M.
    Improta, S.
    Lucania, A.
    Villa, M. R.
    Mastrullo, L.
    LEUKEMIA RESEARCH, 2007, 31 : S75 - S76
  • [40] WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation
    Ling Zhong
    Lingling Wei
    Jiao Chen
    Xiaobing Huang
    Yuping Gong
    Yanrong Lu
    Molecular Diagnosis & Therapy, 2015, 19 : 205 - 212
12345